Arena Pharmaceuticals
From Wikipedia, the free encyclopedia
 |
|
| Type | Public (NASDAQ: ARNA) |
|---|---|
| Industry | Biotechnology |
| Headquarters | San Diego, California, USA |
| Key people | Jack Lief, cofounder and CEO Dominic Behan, co-founder and senior scientist |
| Products | in development |
| Revenue |  US$10.4M (FY 2009)[1] |
| Operating income |  US$-138M (FY 2009)[1] |
| Net income | US$-153M (FY 2009)[1] |
| Total assets | US$236M (FY 2009)[2] |
| Total equity | US$74.6M (FY 2009)[2] |
| Website | www.arenapharm.com |
Arena Pharmaceuticals, Inc. is a biopharmaceutical company located in San Diego, California. The company is developing oral medications that target G-protein-coupled receptors. Currently none of the drugs is approved by the U.S. Food and Drug Administration, but several are in Phase I to III testing, namely (stand January 2009):
- Lorcaserin, Phase III , indication: obesity.
- APD791, Phase I, indication: arterial thrombosis.
- APD916, entering Phase I, indication: pulmonary hypertension.
- Niacin receptor antagonist, Phase I, indication: arteriosclerosis, (in conjunction with Merck)
- APD597, Phase II, indication: diabetes type 2, (in conjunction with Ortho-McNeil-Janssen)
[edit] See also
[edit] References
- ^ a b c Arena Pharmaceuticals (ARNA) annual SEC income statement filing via Wikinvest.
- ^ a b Arena Pharmaceuticals (ARNA) annual SEC balance sheet filing via Wikinvest.
[edit] External links
 |
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
